Jack Vu, MD - Artemis Institute for ...

Dr. Jack Vu, MD

Claim this profile

Artemis Institute for Clinical Research

Studies Coronavirus
Studies Migraine
5 reported clinical trials
13 drugs studied

Affiliated Hospitals

Image of trial facility.
Artemis Institute For Clinical Research

Clinical Trials Jack Vu, MD is currently running

Image of trial facility.

Multiple Treatments

for Chronic Pain

This trial is testing different treatments for chronic pain in patients with knee osteoarthritis, chronic low back pain, and diabetic nerve pain. It aims to find effective ways to reduce their chronic pain.
Recruiting0 awards Phase 26 criteria
Image of trial facility.

IHL-42X

for Obstructive Sleep Apnea

The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnoea who are intolerant, non-compliant, or naïve to positive airway pressure. Phase II study will be a 4-week dose-finding study comparing two dose strengths of IHL-42X to placebo. The optimal dose strength will be selected based on comparing the safety and efficacy of the two IHL-42X dose strengths to placebo over a 4-week treatment period. The three treatment groups are; IHL-42X Low dose (2.5mg dronabinol, 125mg acetazolamide), IHL-42X High dose (5mg dronabinol, 250mg acetazolamide) and Placebo. Each treatment group will enrol approximately 40 patients per treatment arm, for a total of approximately 120 patients. The safety and efficacy results of the Phase II study will be used to select the dose strength of IHL-42X and corresponding doses of dronabinol and acetazolamide in Phase III. Phase III study will use the optimal dose strength of IHL-42X identified in Phase II and will be compared to the component active pharmaceutical ingredients at equivalent dose strengths to those found in the IHL-42X optimal dose strength and placebo over 52 weeks. The four treatment groups are; IHL-42X (optimal dose from Phase II), Acetazolamide (equivalent dose strength to that in the IHL-42X optimal dose strength), Dronabinol (equivalent dose strength to that in the IHL-42X optimal dose strength) and placebo. The treatment groups will enrol approximately 165 patients in IHL-42X, approximately 55 patients in dronabinol, approximately 55 in acetazolamide, and approximately 165 in placebo, for a total of approximately 440 patients.
Recruiting0 awards Phase 2 & 34 criteria

More about Jack Vu, MD

Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jack Vu, MD has experience with
  • Placebo
  • NVX-CoV2373
  • NVX-CoV2540
  • NVX-CoV2601
  • Rehaler Partial Rebreathing Device
  • Sham Breathing Device

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jack Vu, MD specialize in?
Is Jack Vu, MD currently recruiting for clinical trials?
Are there any treatments that Jack Vu, MD has studied deeply?
What is the best way to schedule an appointment with Jack Vu, MD?
What is the office address of Jack Vu, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security